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ARTICLE
Complete chemical structures of human
mitochondrial tRNAs
Takeo Suzuki1, Yuka Yashiro1, Ittoku Kikuchi1, Yuma Ishigami1, Hironori Saito2,3, Ikuya Matsuzawa1,
Shunpei Okada1,4, Mari Mito2, Shintaro Iwasaki 2,3, Ding Ma1, Xuewei Zhao1, Kana Asano1, Huan Lin1,5,
Yohei Kirino 6, Yuriko Sakaguchi1 & Tsutomu Suzuki 1✉
Mitochondria generate most cellular energy via oxidative phosphorylation. Twenty-two
species of mitochondrial (mt-)tRNAs encoded in mtDNA translate essential subunits of the
respiratory chain complexes. mt-tRNAs contain post-transcriptional modifications introduced
by nuclear-encoded tRNA-modifying enzymes. They are required for deciphering genetic
code accurately, as well as stabilizing tRNA. Loss of tRNA modifications frequently results in
severe pathological consequences. Here, we perform a comprehensive analysis of post-
transcriptional modifications of all human mt-tRNAs, including 14 previously-uncharacterized
species. In total, we find 18 kinds of RNA modifications at 137 positions (8.7% in 1575
nucleobases) in 22 species of human mt-tRNAs. An up-to-date list of 34 genes responsible
for mt-tRNA modifications are provided. We identify two genes required for queuosine (Q)
formation in mt-tRNAs. Our results provide insight into the molecular mechanisms under-
lying the decoding system and could help to elucidate the molecular pathogenesis of human
mitochondrial diseases caused by aberrant tRNA modifications.
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M itochondria are eukaryotic organelles that generatechemical energy in the form of ATP through a processreferred to as oxidative phosphorylation (OXPHOS)1.
Hundreds to thousands of copies of mitochondrial (mt)DNAs are
present within this organelle, implying that an endosymbiotic
event took place when the ancestors of eukaryotes took in aerobic
bacteria (in particular, Rickettsiales or close relatives) during early
eukaryotic evolution. Human mtDNA is a circular and double-
stranded DNA, 16,569 base pairs in length, which encodes 37
genes: 13 for the essential subunits of respiratory chain complexes
I, III, IV, and V; 22 for tRNAs (mt-tRNAs); and two for rRNAs
(mt-rRNAs)2. To translate those 13 mRNAs, mitochondria have
their own protein synthesis machinery consisting of mitochon-
drial ribosomes (mitoribosomes), mt-tRNAs, and several trans-
lational factors3. The human mitoribosome contains ~80
ribosomal proteins as well as two mt-rRNAs (16S and 12S
rRNAs) and mt-tRNAVal as structural components4,5. Thus, all
RNA components required for mitochondrial translation are
supplied by mitochondria themselves, whereas all the protein
components, including ribosomal proteins, translational factors,
aminoacyl-tRNA synthetases, and various factors required for
processing and modification of RNAs, as well as biogenesis of
mitoribosome, are encoded in the nuclear genome. They are
translated in cytoplasm and imported to mitochondria.
In mammalian mitochondria, the decoding system is deviated
from the canonical genetic code; AUA for Met, UGA for Trp, and
AGR (R=A and G) for stop codons (see Table 1). The resultant
60 sense codons are deciphered by the 22 species of mt-tRNAs,
which are the minimum set of tRNAs required for a decoding
system in any organism and organelle6. To decrease the number
of tRNAs required, all four codons in each family box are
decoded by a single tRNA with unmodified uridine at the wobble
position (position 34), as unmodified U34 can read any of four
bases at the third position of a codon via a mechanism called
four-way wobbling. On the other hand, two codon sets ending in
purines are decoded by a tRNA with modified uridine at the
wobble position, as this modification prevents misreading of
pyrimidine-ending codons and stabilizes wobble pairing with G-
ending codons. This is a general rule of the mitochondrial
decoding system. In mammalian mitochondria, 5-
taurinomethyluridine (τm5U) is present at the wobble position
in mt-tRNAs for Leu and Trp, and its 2-thiouridine derivative
(τm5s2U) is present at the same position in the mt-tRNAs for Lys,
Glu and Gln7,8. These modifications play critical roles in accurate
decoding of cognate codons. In fact, structural analysis of the
ribosomal small subunit revealed that τm5U34-G3 pair uses
Watson–Click geometry to stabilize the codon–anticodon inter-
action, possibly due to a favorable stacking interaction with the
neighboring A35-U2 pair9.
Disorders of human mitochondrial translation result in mito-
chondrial dysfunction with respiratory defects, and often cause
severe clinical symptoms6. To date, 751 pathogenic mutations in
mtDNA have been reported, of which 300 are in specific mt-
tRNA genes (http://www.mitomap.org/MITOMAP)10. Patho-
genic point mutations in mt-tRNAs are strongly associated with
mitochondrial diseases11,12. We observed severe impairment of
τm5U modification in mutant tRNAs isolated from the cells of
patients with mitochondrial encephalomyopathies6,13. mt-
tRNALeu(UUR)-bearing pathogenic mutations including A3243G,
U3271C, or other mutations associated with MELAS (mito-
chondrial myopathy, encephalopathy, lactic acidosis, and stroke-
like episodes) lack τm5U34 (refs. 14,15), indicating that each of
MELAS mutation hinders recognition by GTPBP3/MTO1, the
enzymatic complex responsible for the τm5U modification16.
Biochemical studies revealed that the hypomodified mt-
tRNALeu(UUR) lacking τm5U34 decodes the UUG codon less
efficiently than the UUA codon17. In fact, mitochondrial ribosome
profiling revealed that mitoribosomes stall at UUG codons in
cybrid cells bearing A3243G mutation as well as in MTO1-
knockout cells18. The hypomodified tRNA does not efficiently
translate ND6, an essential component of complex I, because UUG
codons are abundant in this gene17. This molecular mechanism
explains the complex I deficiency observed in MELAS patients.
Furthermore, the τm5s2U34 modification is not formed in mt-
tRNALys with the A8344G mutation, which is associated with
MERRF (myoclonus epilepsy associated with ragged red fibers)19.
The hypomodified mt-tRNALys does not decipher its cognate
codons efficiently20, impairing mitochondrial protein synthesis
and leading to defects in respiratory activity. These findings pro-
vided the first instances of human diseases caused by aberrant
RNA modification, now referred to as RNA modopathy16.
5-Formylcytidine (f5C), another unique modification in
mammalian mitochondria21, is present at the wobble position of
mt-tRNAMet. f5C34 is required to decipher the non-universal
Table 1 Codon–anticodon pairing in the human mitochondrial genetic code.









(GCA)UUC UCC UAC UGC
UUA Leu
(τm5UAA)
UCA UAA Stop UGA Trp












CUC CCC CAC CGC
CUA CCA CAA Gln
(τm5s2UUG)
CGA



























GUC GCC GAC GGC
GUA GCA GAA Glu
(τm5s2UUC)
GGA
GUG GCG GAG GGG
Non-universal genetic codes are shown in bold: AUA for Met, UGA for Trp, and AGA/AGG for Stop. The anticodon sequences of each tRNA are indicated in parentheses.
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AUA codon as Met as well as the canonical AUG codon22,23. We
and others demonstrated that NSUN3 and ALKBH1 synthesize
f5C34 (refs. 24–27), and we identified two pathogenic point
mutations in mt-tRNAMet that impair f5C34 formation24.
N6-threonylcarbamoyladenosine (t6A) is a bulky modification
found at position 37 (3′ adjacent to the anticodon) of tRNAs
responsible for codons starting with A. t6A is a highly conserved
and essential modification that plays critical roles in protein
synthesis including aminoacylation, decoding, translocation, and
so on. We showed that YRDC and OSGEPL1 are responsible for
t6A37 formation, utilizing L-threonine, ATP, and CO2/bicarbo-
nate as substrates28. Curiously, t6A37 is dynamically regulated by
sensing intracellular CO2/bicarbonate concentration, suggesting
that mitochondrial translation is modulated by t6A37 status28.
We found 15 types of pathogenic mutations in mt-tRNA genes
that impaired t6A37 formation, and confirmed that the levels of
t6A37 were low in mt-tRNAThr bearing the A15923G mutation
isolated from the cells of a patient with MERRF-like symptoms28.
Early linkage analyses and recent genome-wide association
studies with exome sequencing revealed pathogenic mutations in
mt-tRNA-modifying enzymes associated with specific disorders;
PUS1 in mitochondrial myopathy and sideroblastic anemia29;
MTU1 in acute infantile liver failure30–33; GTPBP3 in hyper-
trophic cardiomyopathy, lactic acidosis, and encephalopathy or
Leigh syndrome34,35;MTO1 in hypertrophic cardiomyopathy and
lactic acidosis36–38; TRIT1 in encephalopathy and myoclonic
epilepsy39; and NSUN3 in combined mitochondrial respiratory
chain complex deficiency27. Genetic studies with mouse models
revealed the significant roles of Cdk5rap1 in OXPHOS deficiency
and cardiomyopathy40,Mto1 in cardiomyocytes41,42, andMtu1 in
liver failure43.
To achieve a deeper understanding of human mt-tRNA
modifications associated with molecular pathogenesis of human
mitochondrial diseases, it is necessary to obtain a complete pic-
ture of post-transcriptional modifications in all 22 species of
human mt-tRNAs. To date, only eight species of human mt-
tRNAs have been sequenced and their post-transcriptional
modifications determined. In a previous comprehensive analy-
sis, we mapped 15 types of modified bases at 118 positions in all
species of bovine mt-tRNAs8, providing useful information for
predicting human mt-tRNA modifications and their modifying
enzymes. In this study, we isolate all 22 species of human mt-
tRNAs and analyze the primary sequence and post-
transcriptional modifications for each tRNA using RNA mass
spectrometry in combination with biochemical analyses to map
pseudouridines. In total, we identify 18 species of modified
nucleosides at 137 positions in the 22 species of human mt-
tRNAs. Here, we provide a complete list of mt-tRNA-modifying
enzymes, which should facilitate investigations of their
physiological roles.
Results
Isolation of all 22 species of human mt-tRNAs. To date, eight
species of human mt-tRNAs with post-transcriptional modifica-
tions have been analyzed: Asp44, Ile45, Lys7,46, Leu(UUR)7,47, Leu
(CUN)48, Pro49, Ser(UCN)50, and Ser(AGY)51. To conduct a
comprehensive analysis of human mt-tRNA modifications, we
used our established platforms for RNA isolation, chaplet column
chromatography52, and reciprocal circulating chromatography53.
Using these techniques, we successfully isolated all 22 species of
human mt-tRNAs from human placenta (Fig. 1) and several
species of mt-tRNA from HeLa cells.
Mass spectrometric analysis of human mt-tRNAs. We con-
ducted mass spectrometric analyses of 15 species of mt-tRNAs to
identify post-transcriptional modifications (Fig. 2, Supplemen-
tary Fig. 1, Supplementary Data 1). A typical example of mod-
ification mapping of human mt-tRNACys (Fig. 2a) is shown in
Fig. 2. First, we conducted LC/ESI-MS nucleoside analysis using
hydrophilic chromatography (HILIC)54 to detect modified
nucleosides in mt-tRNACys; the results revealed N6-iso-
pentenyladenosine (i6A), 1-methylguanosine (m1G), pseudour-
idine (Ψ), and 1-methyladenosine (m1A) (Fig. 2b). The presence
of N6-methyladenosine (m6A) (Fig. 2b) is probably due to
spontaneous conversion from m1A to m6A by the Dimroth
rearrangement55 during purification and handling of tRNA.
Second, we used capillary LC/nano ESI-MS to analyze RNA
fragments digested by RNase T1 (Fig. 2c) and RNase A (Fig. 2d);
this method revealed unmodified as well as modified fragments.
To sequence and map the modified nucleosides, each fragment
was further probed by collision-induced dissociation (CID).
Unmodified fragments were unequivocally assigned to fragment
sequences deduced from the reference mt-tRNA sequence by
comparing the observed and calculated m/z values (Fig. 2c, d,
Supplementary Data 1). The internal fragments have 5′-hydroxyl
(5′OH) and 3′-phosphate (3′p) groups, whereas pAGp and
CUUCCAOH were respectively assigned to the 5′- and 3′-term-
inal fragments of mt-tRNACys (Fig. 2c, Supplementary Data 1)
because mature tRNAs generally have 5′-monophosphate and 3′-
hydroxyl groups. RNA fragments containing modified nucleo-
sides can be assigned based on the difference between the
observed mass and calculated m/z value of the unmodified
fragment. For instance, we found a species with m/z 661.1, which
corresponds to a doubly charged anion of 5′-AAACp-3′ with
single methylation (Fig. 2e). CID analysis made it possible to
deduce that the fragment sequence was 5′-AAACp-3′ in which
the second A was methylated (Fig. 2f). Judging from the
nucleoside analysis (Fig. 2b), it turned out to be m1A58 in
Am1AACp (Fig. 2a, f). However, m1A58 was a minor mod-
ification with 17% frequency (Fig. 2e). Likewise, m1G and i6A
were assigned at positions 9 and 37, respectively (Fig. 2a).
According to the mass chromatograms (Fig. 2c, d), frequencies of
m1G9 and i6A37 are quite high with 100% and 99%, respectively
(Supplementary Data 1 and 2).
Finally, we conducted whole-mass analysis of intact tRNA to
validate our assignment. By deconvoluting multiply charged ions
of mt-tRNACys, we calculated the observed mass to be 22271.1 Da
(Fig. 2g). Human mt-tRNACys, which is composed of 69
nucleotides including m1G, i6A and m1A, was calculated to have
a mass of 22286.0 Da. Given that m1A is a minor modification
and its frequency is quite low, the hypomodified tRNA was
calculated to have a mass of 22272.0 Da which is consistent with
the observed mass.
Mapping of Ψ in human mt-tRNAs. To analyze pseudouridine
(Ψ), a mass-silent modification, we treated the tRNA with
A C D E F G H l K L
(AGY)(UCN)(CUN)(UUR)C
ru
de L M N P Q R S S T V W Y
Fig. 1 Isolation of human mitochondrial tRNAs. Urea-denaturing gel
electrophoresis of 22 species of human mt-tRNAs isolated from human
placenta by chaplet column chromatography. The “crude” lane stands for
placental total RNA. Each tRNA species is denoted by the single-letter
abbreviation of the corresponding amino acid.
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acrylonitrile to derivatize Ψ, allowing it to be detected by mass
spectrometry (CE-Ψ-MS)56. As a result of this treatment, Ψ is
cyanoethylated and converted to 1-cyanoethylpseudouridine
(ce1Ψ), which increases the mass by 53 Da. The cyanoethylated
tRNA was digested by RNases and subjected to capillary LC/nano
ESI-MS57–59. In human mt-tRNACys, three cyanoethylated frag-
ments were detected in the RNase T1 digest (Supplementary
Data 1), and each fragment was further analyzed by CID. As
shown in Fig. 3a, ce1Ψ was detected at position 39 by assigning
the product ions of CAi6AAce1ΨUCGp. In CE-Ψ-MS,
acrylonitrile could derivatize τm5(s2)U (Supplementary Fig. 2a, b)
and queuosine (Q) (Supplementary Fig. 3a, b), in addition to
ce1Ψ, probably due to cyanoethylation of the secondary amino
group of the side chain moieties of τm5(s2)U and Q by aza-
Michael addition. We employed this method and analyzed Ψs in
the other 11 species of mt-tRNAs (Supplementary Data 3). The
greatest advantage of CE-Ψ-MS is that it can detect Ψ in the 3′
terminal region of RNAs, whereas no biochemical methods can
detect Ψ in these regions. In fact, we identified two new Ψs at
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Fig. 2 Mass spectrometric analyses of human mt-tRNACys for assignment of post-transcriptional modifications. a Secondary structure of mt-tRNACys
with modifications. “p” and “OH” stand for 5′-monophosphate and 3′-hydroxy termini, respectively. Symbols for modified nucleosides are as follows: m1G
1-methylguanosine, Ψ pseudouridine, i6A N6-isopentenyladenosine, m1A 1-methyladenosine. Watson–Crick and G–U pairs are indicated by solid lines and
asterisks, respectively. b HILIC-MS nucleoside analysis of mt-tRNACys. Left panels: UV chromatogram at 254 nm indicating four unmodified nucleosides
(top panel), extracted-ion chromatograms (XIC) for the protonated ion of i6A (m/z 336) (second panel), m1G (m/z 298) (third panel), Ψ (m/z 245)
(fourth panel), and m1A (m/z 282) (bottom panel). U and N6-methyladenosine (m6A) are also detected in the XIC of Ψ and m1A, respectively. Right
panels: Mass spectra of i6A (upper panel) and m1G (lower panel). Dissociation of a base ion is indicated by a dotted line in each chemical structure.
c, d RNA fragment analysis of mt-tRNACys digested by RNase T1 c and RNase A d. Assigned fragments (Supplementary Data 1) are indicated in the base
peak chromatogram (BPC). p and >p represent the terminal phosphate and 2′,3′-cyclic phosphate, respectively. e XICs of A58-containing fragments of mt-
tRNACys digested by RNase A with (upper panel) or without (lower panel) single methylation. The m1A-containing fragment is indicated. The asterisk
shows a fragment containing m6A which is produced from m1A by the Dimroth reaction. The frequency of m1A is calculated from the summed peak
intensities of the m1A- and m6A-containing fragments versus the non-methylated fragment. Sequence, m/z value, and charge state of each fragment are
shown on the right. f Collision-induced dissociation (CID) spectrum of the RNase A-digested fragment of mt-tRNACys. The doubly charged negative ion of
the RNA fragment (m/z 661.1) was used as the precursor for CID. g Whole-mass analysis of intact mt-tRNACys. A series of multiply charged negative ions
with charge values are shown in the mass spectrum. The deconvoluted molecular mass is shown in the inset.
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(Fig. 3b), although the post-transcriptional modifications of this
tRNA were reported previously49. We also detected Ψ at position
68 in human mt-tRNAAla (Supplementary Data 3).
In addition to mass spectrometric analyses, we performed
biochemical mapping of Ψ in mt-tRNAs. Ψ can be derivatized by
the water-soluble carbodiimide CMC [N-cyclohexyl-N′-(2-
morpholinoethyl)carbodiimide methyl-p-toluenesulfonate]. N3-
derivatized Ψ (CMC-Ψ) can be detected by primer extension
(CMC-PE)60, as N3-substitution hinders extension of cDNA
when tRNA is reverse-transcribed. To perform the mapping, we
treated total RNA from HeLa cells with CMC and used it as a



































































































































































Fig. 3 MappingΨ sites in human mt-tRNAs. a A CID spectrum of the RNase T1-digested fragment of human mt-tRNACys. The doubly charged negative ion
of the cyanoethylated RNA fragment (m/z 1345.7) was used as the precursor for CID. Asterisks in the spectrum denote product ions containing ce1Ψ.
b A CID spectrum of the cyanoethylated RNA fragment to determine the site for Ψs in human mt-tRNAPro. The triply charged negative ion of the mono-
cyanoethylated RNA fragment (m/z1266.5) was used as the precursor for CID. Assignment of the product ions revealed the presence of two fragments
containing ce1Ψ66 and ce1Ψ67. Asterisks in the spectrum denote product ions containing ce1Ψ. c CMC-PE analysis for detection of Ψ sites in human mt-
tRNACys. HeLa total RNA treated with (+) or without (−) CMC was reverse-transcribed with a primer specific to human mt-tRNACys. The sequence
ladders for U and A were generated under the same conditions in the presence of ddATP and ddTTP, respectively. The positions for Ψs and sequence are
shown with the gel image. Source data are provided as a Source Data file. d Diagram of tRNA-Ψ-seq. Detailed procedure is described in the “Methods”
section. e IGV snapshots of tRNA-Ψ-seq for human mt-tRNAGly and mt-tRNAVal. Histograms of mapped reads are shown for each tRNA when tRNA-Ψ-seq
was performed in the absence (−) or presence (+) of CMC. The RT-stop signature for CMC-Ψ (indicated by red arrowheads) can be observed as a sudden
drop in the number of piled reads.
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individual tRNA was reverse-transcribed by a 32P-labeled primer.
The radiolabeled cDNAs were resolved by PAGE analysis and
visualized by a fluoroimager. As shown in Fig. 3c, three CMC-Ψ
sites were clearly detected at positions 27, 28, and 32 of mt-
tRNACys when we used CMC-treated total RNA as a template.
We then applied CMC-PE to analyzed Ψs in the other eight
species of mt-tRNAs (Supplementary Fig. 4, Supplementary
Data 3). By combining the CE-Ψ-MS data and published
information, we detected 52 Ψ sites in 22 species of human mt-
tRNAs (Supplementary Data 3 and 4).
CMC-Ψs can be detected in a transcriptome-wide manner by
deep sequencing61. We applied this technique to mapping Ψ in
tRNAs (tRNA-Ψ-seq) (Fig. 3d). For this purpose, we treated
human tRNA fraction with Escherichia coli AlkB to demethylate
m1A, 3-methylcytidine (m3C), m1G, N2-methylguanosine (m2G),
and N2, N2-dimethylguanosine (m2,2G) that prevent cDNA
extension62, followed by derivatizing Ψs in the resultant tRNAs
with CMCT. cDNA libraries prepared with or without CMC
treatment were subjected to deep sequencing, and sufficient data
for both conditions were mapped to human mt-tRNA genes. The
RT-stop signature for CMC-Ψ was calculated and designated the
Ψ score (Supplementary Data 3). Typical examples of tRNA-Ψ-
seq are shown in Fig. 3e. Because tRNA-Ψ-seq cannot detect Ψs
in the 3′ terminal region of tRNA, three Ψ sites at positions 66–68
of mt-tRNAs for Ala and Pro were excluded in this analysis.
Based on the scores, 44 of 49 sites were detected by tRNA-Ψ-seq,
whereas five sites detected by CE-Ψ-MS and/or CMC-PE were
not (Supplementary Data 3). The inconsistency in these results
might be explained by differences between the cell lines in these
experiments or by differences in detection efficiency.
Full complement of RNA modifications in human mt-tRNAs.
In addition to mt-tRNACys, we analyzed the other 13 mt-tRNAs
whose modifications had not been previously reported (Fig. 4a,
Supplementary Fig. 1, Supplementary Data 4). Of those, we
analyzed mt-tRNAGlu by a conventional post-labeling method
using two-dimensional thin-layer chromatography (2D-TLC)
(Supplementary Fig. 5); eight modifications were clearly identified
(Supplementary Data 4). Based on the peak intensities of XICs
between the modified and unmodified RNA fragments, we cal-
culated modification frequencies for 51 sites in 15 species of mt-
tRNAs (Supplementary Data 1 and 2).
m1A9 and m2G10 are quite abundant modifications found in
eight mt-tRNA species. Their frequencies are high in six species
of them, whereas hypomethylation was found in Phe and His.
Exclusively in mt-tRNAArg, m1A is present at position 16 in
the D-loop. Judging from mass chromatographic peak ratio
between modified and unmodified fragments, we estimated the
modification frequency of m1A16 to be about 20% (Fig. 5a).
Partially modification of m1A16 in this tRNA was reported
previously63.
In mammalian mitochondria, τm5U is present at the wobble
position (position 34) in mt-tRNAs for Leu(UUR) and Trp,
whereas τm5s2U is present at the corresponding positions in mt-
tRNAs for Lys, Glu, and Gln6,8. In human mitochondria, τm5U
and τm5s2U are present at position 34 of the mt-tRNAs for Leu
(UUR) and Lys, respectively7. In this study, we confirmed the
presence of τm5U34 in human mt-tRNATrp with 79% frequency
(Fig. 5b), and τm5s2U34 in the human mt-tRNAs for Glu
(Supplementary Fig. 5) and Gln (Fig. 5c). Modification status of
the wobble position of mt-tRNAGln is quite complex with
τm5s2U34 (67%), τm5U34 (12%), s2U34 (11%), and U34 (8%)
(Supplementary Data 2). In addition, we detected a small amount
of 5-carboxymethylaminomethyluridine (cmnm5U, 0.6%) in mt-
tRNATrp (Fig. 5b), and carboxymethylaminomethyl-2-thiouridine
(cmnm5s2U, 1.3%) in mt-tRNAGln (Fig. 5c). We previously
reported that cmnm5U and cmnm5s2U are observed in mt-tRNAs
under depletion of taurine16. cmnm5(s2)U are naturally present in
these tRNAs under normal growth condition.
According to previous studies8, Q is present at position 34 of
mammalian mt-tRNAs for Tyr, His, Asp, and Asn. In addition to
Q34 in human mt-tRNAAsp44, we detected Q34 in the other
three tRNAs.
We assumed that human mt-tRNAMet contains 5-
formylcytidine (f5C) and two Ψs, based on bovine mt-tRNAMet
sequence21,64 (Spremulli, L. L., personal communication). In
addition to Ψ27, Ψ50, and f5C34, which were predicted, we
detected Ψ55 in this tRNA. As we reported previously24, f5C34 is
fully introduced to human mt-tRNAMet (Supplementary Data 2).
2-Methylthio-N6-isopentenyladenosine (ms2i6A) is present at
position 37 in mt-tRNAs for Phe, Ser(UCN), Trp, and Tyr.
Although the frequency of this modification is quite high in Phe
(93%) (Supplementary Data 2), it is partially introduced to Trp
(ms2i6A= 51%, i6A= 31%) (Fig. 5b, Supplementary Data 2) and
Tyr (ms2i6A= 45%, i6A= 17%) (Fig. 5d, Supplementary Data 2).
t6A is another critical modification at position 37 of mt-tRNAs
for Ile, Lys, Asn, Ser(AGY), and Thr. It is fully introduced to Thr
(97%) and partially to Asn (42%) (Fig. 5e) and Ser(AGY) (74%)
(Supplementary Data 2).
m1G is present at position 37 of mt-tRNAs for Ala, Leu(CUN),
Pro, and Gln. It is completely introduced to Ala, Pro, and Gln
(Supplementary Data 2).
5-Methyluridine (m5U), so-called ribothymidine, is present at
position 54 of five mt-tRNAs. Since bovine mt-tRNAs do not
have this modification8, m5U54 is a modification unique to
human mt-tRNAs. Rate of m5U54 is quite high in mt-tRNAs for
Pro (98%) and Asn (95%), but low in mt-tRNAGln (33%) (Fig. 5f,
Supplementary Data 2).
5-Methylcytidines (m5C) is present in six species of human mt-
tRNAs27,65,66. The rate of m5C is quite high in Phe (91%), His
(100%), and Tyr (89%) (Supplementary Data 2). Three consecutive
m5C are present at positions 48–50 in mt-tRNASer(AGY). About
80% of this tRNA has all three m5Cs, whereas the rest 20% has two
of them (Supplementary Data 2).
In mt-tRNAHis, we detected two kinds of RNase T1-digested
fragments with different residues at position 47 (A47 and U47)
(Supplementary Fig. 1, Supplementary Data 1). According to the
database of polymorphilic mutations in human mtDNA, this
variation is derived from A12180T mutation in a type of
haplogroup A2 [GenBank accession number KJ923817.1
(ref. 67)], suggesting that this heteroplasmy for this mutation is
harmless. Intriguingly, the A47 variant has m5C48 (100%),
whereas the U47 variant has no m5C48 (Supplementary Data 1).
In addition, we also detected addition of G−1 to the 5′ terminus of
this tRNA mediated by THG1L68.
Biogenesis of Q34 in human mt-tRNAs. In human cytoplasm,
Q34 is present in several cytoplasmic tRNAs responsible for NAY
codons. Q34 is synthesized by tRNA guanine transglycosylase
(TGT), which catalyzes substitution of guanine with queuine, a
nucleobase of Q34 (ref. 69). Unlike the bacterial TGT which is a
single protein, eukaryotic TGT consists of a catalytic subunit
QTRT1 and a non-catalytic subunit QTRT2 (formerly known as
QTRTD1)70. Both QTRT1 and QTRT2 are required for Q34
formation on cytoplasmic tRNAs. We here identified Q34 in four
species of human mt-tRNAs. To examine whether QTRT1 and
QTRT2 are also required for Q34 biogenesis of mt-tRNAs, we
knocked out QTRT1 and QTRT2 in HEK293T cells by CRISPR/
Cas9 system (Fig. 6a). We then isolated the mt-tRNAs for Asp,
His, Asn, and Tyr from WT and KO cells, and subjected them to
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LC/MS nucleoside analysis. We detected no Q signal in any of
mt-tRNA isolated from cells harboring knockout of QTRT1 or
QTRT2 (Fig. 6b), demonstrating that both genes are required for
Q34 biogenesis of mt-tRNAs.
To pursue functional relevance of this modification, we have
carried out mitoribosome profiling of QTRT2 KO versus wild-
type HEK293T cells, and calculated codon occupancy change
upon QTRT2 KO. As shown in Fig. 6c, the codon occupancy at
UAU codon increased significantly upon QTRT2 KO, indicating
that Q34 in mt-tRNATyr plays a role in efficient decoding of UAU
codon in mitochondria. Dysregulation of cytoplasmic translation
upon queuine depletion results in unfolded proteins that trigger
endoplasmic reticulum stress and activation of the unfolded
protein response in human cell lines71. To characterize cellular
protein homeostasis in QTRT2 KO, we measured the formation
of protein aggregates using destabilized variants (R188Q and
R188Q/R261Q) of firefly luciferase (Fluc) fused with EGFP72. The
EGFP-tagged Fluc variant is a sensitive reporter to measure the
formation of protein aggregates. As shown in Fig. 6d, EGFP foci
due to folding problem of Fluc variants significanly increased in
QTRT2 KO compared with WT in both reporters with single and
double mutations. Even in the reporter without mutation, the
aggregation rate of QTRT2 KO was highly than that of WT. This
result strongly suggests that a protein folding problem takes place
in QTRT2 KO due to lack of Q34 in both cytoplasmic and
mitochondrial tRNAs.
Discussion
Here, we report the post-transcriptional modifications in 14 spe-
cies of human mt-tRNAs. Together with previously published
information for the eight mt-tRNAs, somewhat revised on the
basis of our findings, we now have a complete picture of post-
transcriptional modifications of human mt-tRNAs (Supplemen-
tary Data 4), comprising 18 types of RNA modifications at 137
positions (8.7% of 1575 total residues) (Fig. 7). All modifications
are summarized in cloverleaf structures of 22 human mt-tRNAs
(Supplementary Fig. 6). Notably, the absence of 2′-O-methylation
is a characteristic feature of mammalian mt-tRNAs. The numbers
of modified sites range from three to nine, corresponding to
4.2–12.7% of tRNA residues. Human mt-tRNAVal is the least
modified tRNA, bearing only three sites, m1A9, m2G10, and Ψ39,
tRNAAla
tRNAMet
tRNAVal tRNATrp tRNATyr tRNAPro

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 Post-transcriptional modifications in 14 human mt-tRNAs. a Secondary structure of 13 human mt-tRNAs with post-transcriptional modifications.
Symbols for modified nucleosides are as follows: m2G N2-methylguanosine, m5C 5-methylcytidine, ms2i6A 2-methylthio-N6-isopentenyladenosine, D
dihydrouridine, m5U 5-methyluridine. The A/U in mt-tRNAHis indicates that both A and U were detectable at this position as a result of heteroplasmy in
the sample. b Secondary structure of human mt-tRNAPro, including unreported Ψ at positions 66 and 67.
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whereas mt-tRNAs for Leu(UUR), Asn, Pro, and Gln have the
highest number of modified sites (nine sites).
We previously reported 15 types of RNA modifications at 118
positions in bovine mt-tRNAs8. The larger number of modifica-
tions and modified positions in human mt-tRNAs can be
attributed to the presence of m5U54 and cmnm5(s2)U34 (minor).
Because the 22 species of mt-tRNAs share 81% sequence identity
between human and bovine, it is intriguing to compare tRNA
modifications between the two species. Ninety-seven positions
with modifications are common to both species, whereas 40 and
22 positions are specific to human and bovine mt-tRNAs,
respectively. Seventeen of 40 human-specific positions are not the
same residues with those in bovine mt-tRNAs, indicating natural
loss of modifications by mutations, and conversely, 14 out of 22
are bovine-specific residues. These facts indicate that the mod-
ification system for mt-tRNAs is well-conserved between these
two mammals. Presumably, some alteration in tRNA sequences
between these species modulates positive and negative determi-
nants for each tRNA-modifying enzyme, resulting in differences
in modification status between the species.
In regard to the decoding system of human mitochondria, we


























































































































































20 12 14 16 18 20
Time (min)
Time (min) Time (min)
12
25 27 29 31 33 35




























































































m/z 702.761 (z = –6) m/z 1563.220 (z = –2)
m/z 1540.226 (z = –2)
m/z 1506.195 (z = –2)
m/z 1538.228 (z = –2)
m/z 1515.235 (z = –2)
m/z 1494.712 (z = –2)
m/z 1471.719 (z = –2)
m/z 1437.687 (z = –2)
m/z 1125.18 (z = –1)





m/z 700.425 (z = –6)
m/z 698.090 (z = –6)
m/z 1198.120 (z = –2)
m/z 1190.132 (z = –2)
m/z 1129.913 (z = –2)
m/z 1173.129 (z = –2)
m/z 1121.624 (z = –2)
m/z 711.614 (z = –2)
m/z 688.620(z = –2)
m/z 654.589(z = –2)
Fig. 5 Frequencies of mt-tRNA modifications. Typical XICs of modified and unmodified RNA fragments of the indicated tRNAs digested by RNase T1
(a–c, f) or RNase A (d, e). The frequency of each modification is calculated from peak intensity ratio of the modified and unmodified RNA fragments.
Sequence, m/z value, and charge state of each fragment are shown on the right.
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unmodified U34 in the anticodon (Table 1), demonstrating that
the family boxes are decoded by single tRNAs via the four-way
wobble rule. For NNR codons, all six mt-tRNAs had modifica-
tions at the wobble position: f5C34 in mt-tRNAMet, τm5U34 in
mt-tRNAs for Leu(UUR) and Trp, and τm5s2U in mt-tRNAs for
Lys, Glu, and Gln. These modifications contribute to precise and
efficient recognition of the cognate codons, as well as prevention
of near-cognate codon misreading. Q34 is present in four mt-
tRNAs (Tyr, His, Asn, and Asp) responsible for NAY codons.
Given that pathogenic mutations related to mitochondrial
dysfunction are frequently found in tRNA-modifying enzymes, a
complete list of human genes responsible for mt-tRNA mod-
ifications is necessary to fully appreciate the physiological and
pathological importance of mt-tRNA modifications. In addition,
identification of tRNA-modifying enzymes enables us to study the
biosynthetic pathway responsible for each modification. Based on
the finding in this study, we provide a list of confirmed and
predicted genes responsible for mt-tRNA modifications,
accompanied by information about the human diseases associated
with each gene (Supplementary Table 1). About 30 genes are
responsible for tRNA modifications in human mitochondria.
m5U54 is present in human mt-tRNAs but not in bovine mt-
tRNAs. This is the only modification unique to one of these
species. Very recent works showed that TRMT2B, a mammalian
homolog of bacterial TrmA, is responsible for m5U54 in several
mt-tRNA species, as well as for m5U429 in 12 S rRNA73,74. TrmA
has a catalytic Cys residue which is essential to m5U54 forma-
tion75. Human and mouse TRMT2B conserve this Cys residue,
whereas bovine TRMT2B homolog has a Cys-to-Tyr point
mutation at the corresponding site that inactivates the enzyme.
m3C32 is present in mt-tRNAs for Ser(UCN) and Thr. We and
others previously reported that yeast ABP140/Trm140 is
responsible for m3C32 formation in yeast cytoplasmic
tRNAs76,77. In humans, there are four paralogs of yeast ABP140/
Trm140: METTL2A, METTL2B, METTL6, and METTL8. The
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Fig. 6 QTRT1 and QTRT2 are necessary for Q34 in mt-tRNAs. a Gene structure of the human QTRT1 (upper) and QTRT2 (lower) with mutation sites
introduced by the CRISPR/Cas9 system. The target sequence of the single-guide RNA (sgRNA) is underlined. The protospacer adjacent motif (PAM)
sequence is boxed. Insertion and deletion are indicated by magenta letters and dashed lines, respectively. Electropherogram of Sanger sequence is shown
in each KO cell. b XICs of Q nucleoside of human mt-tRNAs for Asp, His, Asn, and Tyr isolated from WT (top), QTRT1 KO (middle), and QTRT2 KO cells
(bottom). c Boxplot of fold change in the ribosomal A-site codon occupancy of mitoribosome from QTRT2 KO versus WT HEK293T cells. Codon occupancy
is calculated by average of biological replicates (n= 2). Each box shows the first quartile, median, and third quartile. The whiskers represent the 1.5×
interquartile ranges. *P < 1.0 × 10−3 value was calculated by two-sided Wilcoxon rank-sum test. d Proteome stress of QTRT2 KO measured by the firefly
luciferase (Fluc)-based thermal stability sensor fused with enhanced green fluorescent protein (EGFP). The Fluc sensor with no mutation (No mut.), single-
(R188Q) or double-(R188Q/R261Q) mutation was introduced to QTRT2 KO or WT HEK293T cells. The aggregation rate was calculated by dividing the
number of sensor protein aggregates by the area of EGFP fluorescence in each microscopic images. Horizontal lines in the scattered dot plot represent the
first quartile, median, and third quartile from the bottom. P value were calculated by two-sided Wilcoxon rank-sum test. Source data are provided as a
Source Data file.
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METTL8 is responsible for mRNA modification78. It remains to
be determined which paralog is responsible for m3C32 formation
in mt-tRNAs.
Q34, a unique modification with 7-deazaguanosine structure, is
present in both cytoplasmic and mitochondrial tRNAs respon-
sible for NAY codons. Q34 controls the elongation speed of
cognate codons, thereby modulating correct folding of nascent
proteins71. Q34 is present in four mt-tRNAs for Tyr, His, Asn,
and Asp. In this study, we found that both QTRT1 and QTRT2
are essential for Q34 formation in four mt-tRNAs. The physio-
logical impact of queuosine depletion71,79 could be attributed to
hypomodification of Q34 in mt-tRNAs, as well as in cytoplasmic
tRNAs. We here carried out mitoribosome profiling of QTRT2
KO versus wild-type HEK293T cells, and calculated codon
occupancy change upon QTRT2 KO. The occupancy at UAU
codon increased significantly upon QTRT2 KO (Fig. 6c), indi-
cating that Q34 in mt-tRNATyr plays a role in efficient decoding
of UAU codon in mitochondria. In addition, we found a protein
folding problem due to lack of codon optimality in QTRT2 KO
cells (Fig. 6d). However, it is difficult to estimate the effect of Q34
deficiency in mt-tRNAs on the cytoplasmic protein homeostasis.
Our group previously reported that τm5U34 deficiency in mt-
tRNAs induced protein aggregation in cytoplasm42. This fact
naturally speculates that Q34 deficiency in mt-tRNAs could affect
cytoplasmic protein homeostasis to some extent. Recently, it has
been shown that queuine depletion promotes a Warburg type
metabolism with increased glycolysis and glutaminolysis with
increased ammonia and lactate production, causing a decreased
rate of ATP synthesis80. However, no proliferation phenotype was
not observed upon queuine depletion80. Mitochondrial Q34
deficiency could slightly modulate mitochondrial translation and
affect cellular metabolic status.
m1A16 is unique to human mt-tRNAArg. Two methyl-
transferases are responsible for m1A formation in mammalian
mitochondria. TRMT61B introduces m1A58 into several mt-
tRNAs81 and m1A947 in 16S rRNA82. Judging from the con-
sensus loop sequence recognized by TRMT61B, m1A16 might
also be introduced by TRMT61B. On the other hand, m1A9 and
m1G9 in a subset of mt-tRNAs are introduced by the MRPP1
(TRMT10C) and MRPP2 (SDR5C1) complex83.
Ψ is the most abundant modification in human mt-tRNAs84.
Because Ψ is a mass-silent modification, it is necessary to deri-
vatize Ψ with chemical modification, such as cyanoethylation or
CMC addition, in order to detect it. However, because the fre-
quency of Ψ varies at each position and most sites are partially
modified, it is extremely difficult to detect minor sites with low Ψ
frequencies. In addition, the level of Ψ might differ among cell
types and tissues. Moreover, chemical derivatization of Ψ is
strongly affected by tRNA structure, making it even more difficult
to determine and compare the exact frequency of Ψ at different
positions. In this study, we employed three techniques for
detecting Ψ, CE-Ψ-MS, CMC-PE, and tRNA-Ψ-seq, and carefully
mapped Ψ at 52 positions in human mt-tRNAs. Ψ33, Ψ35, Ψ38,
Ψ66, and Ψ68 are present in human, but not in bovine, mt-
tRNAs. Ψ is introduced by isomerization of uridine catalyzed by
Ψ synthase. The human genome encodes 13Ψ synthases85. In this
study, we identified Ψ35 in human mt-tRNAHis, the first time this
modification has been detected in a mammalian mt-tRNA.
Although Ψ35 was previously identified in starfish mt-tRNAAsn
and eukaryotic cytoplasmic tRNATyr86,87, the responsible Ψ
synthase has not yet been identified. Given that yeast Pus7p has
broad substrate specificity and introduces Ψ into U2 snRNA, 5S
rRNA, and cytoplasmic tRNAs, including Ψ35 (ref. 88), human
PUS7 might be involved in formation of Ψ35 in mt-tRNAHis.
Further study is necessary to confirm this prediction. Similarly,
based on the fact that yeast Pus3p introduces Ψ38 and Ψ39 in
cytoplasmic tRNAs, Ψ38 might be introduced by human PUS3.
Human PUS1 is a plausible candidate responsible for Ψ66 and
Ψ68, as Ψ67 is introduced by this enzyme89. Regarding Ψ33, four
Ψ synthases are predicted as candidates.
We identified m5Cs at positions 48–50 in six mt-tRNA species.
Recently, we reported that a fraction of NSUN2 is localized in
mitochondria and introduces m5C in mt-tRNAs66,90.
MTU1 and NFS1 are responsible factors for 2-thiouridine
formation of τm5s2U34 (ref. 91). However, in E. coli and other
bacteria92, five sulfur mediators TusA, B, C, D, and E are required
for 2-thiouridine formation in addition to IscS and MnmA. IscS,
an NFS1 homolog in bacteria, catalyzes desulfuration of L-
cysteine, and transfers a persulfide sulfur to TusA. Then, the
sulfur is transferred to TusD in TusBCD complex, and to TusE.
Finally, TusE interacts with MnmA-tRNA complex and the sulfur
is transferred to the wobble uridine in tRNA mediated by MnmA.
Based on the bacterial studies, the sulfur relay system might also
be involved in mitochondrial 2-thiouridine formation. Some
sulfur mediators could be added to the list of genes.
m2G6 and m5C72 are present in bovine mt-tRNAAsp and mt-
tRNAThr8, respectively, but absent from human mt-tRNAs. It is
likely that A6 in human mt-tRNAAsp simply avoids m2G6
modification. On the other hand, C72 is retained in human mt-
tRNAThr. Some human cytoplasmic tRNAs also have m5C72
formed by NSUN6 methyltransferase93. If bovine NSUN6 has a
weak mitochondria-targeting sequence, the enzyme might be
partially localized to mitochondria, where it introduces m5C72 in
mt-tRNAThr, whereas human NSUN6 might not be imported





























































Fig. 7 Integrated view of post-transcriptional modifications in 22 human
mt-tRNAs. The positions of modifications are indicated by gray circles on
the schematic cloverleaf structure of tRNA with position numbers. At each
position, the symbol of each modification is shown with the number of
tRNA species in parenthesis. The light gray circles and line represent a base
pair between positions 27a and 43a, which are unique to mt-tRNASer(UCN).
The “−1” for G−1 is specific to mt-tRNAHis. The symbol m2,2G represents
N2, N2-dimethylguanosine.
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between human and bovine mt-tRNAsThr might be responsible
for the species-specific m5C72 modification.
Pathogenic point mutations in mt-tRNA genes are associated
with human mitochondrial diseases11. We previously showed that
several mutations in mt-tRNAs associated with MELAS and
MERRF prevent recognition by tRNA-modifying enzymes
responsible for τm5s2U34 formation, resulting in loss of the
wobble modifications6,13. This finding indicates that some
pathogenic point mutations act as negative determinants for
tRNA-modifying enzymes. In addition, if such a point mutation
overlaps with the site to be modified, it would likely eliminate the
modification. Of ~300 tRNA mutations associated with human
diseases in the MITOMAP10, 23 pathogenic point mutations in
13 species of mt-tRNAs can be found in modification sites
(Supplementary Data 5), many of which are present in the tRNA
body, implying that loss of tRNA modification as a result of
pathogenic mutation is a primary cause of mitochondrial disease.
In summary, we have provided a complete list of post-
transcriptional modifications in human mt-tRNAs. This infor-
mation represents a milestone in the study of biological aspects of
tRNA modifications in human mitochondria. Identification of
mt-tRNA-modifying enzymes enables us to investigate and study
the molecular pathogenesis of RNA modopathies associated with
mitochondrial dysfunction. Recent studies have shown that tRNA
modifications are dynamically regulated, and that their fre-
quencies change under various cellular conditions16,28. However,
the currently available methods for analyzing RNA modification
have both advantages and disadvantages. RNA-MS is an ideal and
useful technique for quantifying the exact frequency of any tRNA
modifications, except for Ψ. For this analysis, however, we need to
isolate each tRNA species from various cells and tissues. On the
other hand, epitranscriptome-wide methods based on deep
sequencing technology can be used to quantify a couple of tRNA
modifications in a limited quantity of specimens from various
sources. In the future, we need to develop an innovative and
sensitive technology for quantifying any tRNA modifications
more easily and accurately.
Methods
Isolation of individual mt-tRNAs from human placenta and HeLa cells. Pre-
paration of human placental RNA was performed in the literature17. Briefly, total
RNA was extracted from buffer-homogenized human placenta by phenol extrac-
tion, and the tRNA fraction was roughly fractionated by anion exchange chro-
matography with DEAE Sepharose Fast Flow (GE Healthcare). Twenty-two species
of individual mt-tRNAs were isolated by chaplet column chromatography52. Total
RNA was extracted from HeLa cells using TriPure Isolation Reagent (Roche Life
Science). Several mt-tRNA species were isolated by reciprocal circulating chro-
matography method53. The isolated tRNAs were resolved by denaturing poly-
acrylamide gel electrophoresis with 7M urea and gel-purified. The sequences of
DNA probes for mt-tRNA isolation are listed in Supplementary Data 6.
RNA mass spectrometry. For nucleoside analysis of tRNAs54, the isolated tRNA
(10 pmol) was digested into nucleosides 5′-monophosphate with 0.2 U nuclease P1
(FUJIFILM Wako Pure Chemical) in 10 mM ammonium acetate (pH 5.3) at 37 °C
for 60 min, followed by adding 0.1 U phosphodiesterase I (Worthington) in 50 mM
ammonium bicarbonate (to adjust pH from 5.3 to 8.2) and incubating at 37 °C for
60 min. The digests were dephosphorylated by adding 0.1 U of bacterial alkaline
phosphatase (from E. coli C75; FUJIFILM Wako Pure Chemical) and incubating at
37 °C for 60 min. The digested nucleosides were dissolved in 90% acetonitrile/10%
water, and subjected to a hydrophilic interaction LC (ZIC-cHILIC, 3 μm particle
size, 2.1 × 150 mm; Merck) connected to ESI-MS on a Q Exactive hybrid
Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific), equipped with
an ESI source and an Ultimate 3000 liquid chromatography system (Thermo Fisher
Scientific). The nucleosides were separated at a flow rate of 100 μL/min in a solvent
system consisting of 5 mM ammonium acetate (pH 5.3) (solvent A) and acetoni-
trile (solvent B) in a multistep linear gradient (90–40% B from 0 to 30 min, 40% B
for 10 min, and then initialized to 90% B)54. For queuosine analysis, a linear
gradient was set to starting with 50% B in 0–5 min, 50–10% B in 5–35 min, 10% B
in 35–45 min, and initialized to 50% B in 45–50 min. Protonated ions of nucleo-
sides were scanned in a positive polarity mode over an m/z range of 110–700.
For RNA fragment analysis, the isolated tRNAs (2 pmol) were digested with
RNase T1 (10 U; Thermo Fisher Scientific) in 25 mM ammonium acetate (pH 5.3)
or RNase A (10 ng; Thermo Fisher Scientific) in 25 mM ammonium acetate (pH
7.3) at 37 °C for 60 min. The digests were mixed with one-tenth volume of 0.1 M
triethylamine acetate (pH 7.0), and subjected to capillary LC/nano ESI-MS on an
LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a
splitless nanoflow high-performance LC (nano-HPLC) system (DiNa; KYA
Technologies) using a nano-LC trap column and a capillary column (HiQ Sil
C18W-3, 0.1 × 100 mm; KYA Technologies)57,94. The digested tRNA fragments
were separated at a flow rate of 300 nL/min by capillary LC in a solvent system
consisting of 0.4 M 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (pH 7.0) (solvent A)
and 0.4 M HFIP (pH 7.0) in 50% methanol (solvent B) using a linear gradient
(2–100% B in 40 min)95. The eluent was ionized by an ESI source in negative
polarity mode and scanned over an m/z range of 600–2000. The CID was
performed by data-dependent scan with normalized collision energy 40. The
product ions were assigned as described96.
Qual Browser software bundled in Xcalubur (Thermo Fisher Scientific) was
used for data analysis.
Measuring frequency of mt-tRNA modification. In negative mode of ESI,
detection efficiencies of the RNA fragments having the same sequence but different
modification status do not differ largely, because ESI ionization relies mainly on
numbers of phosphate groups, not on type of base modifications28,97. Hence, we
are able to relatively quantify frequency of tRNA modification at each site from the
extracted-ion chromatogram (XICs) intensities between the modified and unmo-
dified RNA fragments. We analyzed both modified and unmodified fragments for
each site and calculated the modification frequencies (Supplementary Data 1 and
2). Due to technical difficulties, we could not calculate frequencies of all the
modification detected in this study. We here show modification frequencies for
51 sites in 15 species of mt-tRNAs (Supplementary Data 1 and 2).
CE-Ψ-MS. Cyanoethylation of tRNA was performed essentially as described8,56
with slight modification. The isolated tRNA (5–10 pmol) dissolved in ≤4 μL water
was mixed with 30 μL of 41% (v/v) ethanol/1.1 M trimethylammonium acetate (pH
8.6) and 4 μL of acrylonitrile (Fujifilm Wako Pure Chemical Corporation), and
then incubated at 70 °C for 2 h. The cyanoethylated tRNA was collected by ethanol
precipitation and dissolved in water. The solution was then subjected to RNase
digestion and analyzed by RNA mass spectrometry as described above.
CMC-PE. Detection of Ψ sites by CMC derivatization and primer extension was
performed essentially as described60,98,99 with slight modification. HeLa total RNA
(10 μg) was dissolved in 30 μL of CMC solution [0.17 M N-cyclohexyl-N′-(2-
morpholinoethyl)carbodiimide methyl-p-toluenesulfonate (CMC), 7 M urea,
50 mM Bicine, and 4 mM EDTA] and incubated at 37 °C for 20 min. The reaction
was quenched by addition of 100 μL stop solution [0.3 M NaOAc (pH 5.6) and
0.1 M EDTA], followed by addition of 700 μL ethanol to precipitate the RNA. The
RNA pellet was rinsed twice with 70% EtOH and dried. The CMC-derivatized
RNA was dissolved in 40 μL of 50 mM Na2CO3 (pH 10.4), incubated at 37 °C for
4 h (alkaline treatment), ethanol precipitated, and dissolved in 10 μL water. The
treated RNA (1 μg) was mixed with the 5′ 32P-labeled primer (0.1 pmol) in a 5 μL
solution containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA, incubated at
80 °C for 2 min, and cooled to room temperature. Subsequently, reverse tran-
scription was started by adding 0.75 μL water, 2 μL of 5× FS buffer (Invitrogen),
0.25 μL of 1.5 mM dNTP mix, 1.5 μL of 25 mM MgCl2, and 0.5 μL of SuperScript
III (Invitrogen), and the mixture was incubated at 55 °C for 1 h. As a control, the
same reaction was performed with total RNA untreated with CMC. The RNA
sequencing ladder was generated by reverse transcription under the same condition
in the presence of 37.5 μM of ddTTP or ddATP. To stop the reaction and degrade
the template RNA, 0.5 μL of 4M NaOH was added to the reaction mixture, fol-
lowed by boiling at 95 °C for 5 min, and then the reaction was neutralized by
addition of 9 μL of 1M Tris-HCl (pH 5.0). cDNAs were resolved on 12% PAGE
with 7 M urea. The radiolabeled bands were visualized by fluoroimager (FLA-7000;
Fujifilm). Primer sequences are listed in Supplementary Data 5.
tRNA-Ψ-seq. tRNA-Ψ-seq was basically performed essentially as described100–102
with several modifications. Total RNA was extracted from HEK293T cells by acid
guanidinium thiocyanate-phenol-chloroform extraction (AGPC) method103. The
tRNA fraction was separated by 10% PAGE with 7M urea, excised from the gel
and eluted from the gel pieces, subjected to deacylation with 0.1 M CHES-NaOH
buffer (pH 9.0) at 37 °C for 30 min, and ethanol precipitated. The deacylated tRNA
was then demethylated by E. coli AlkB at 37 °C for 3 h in a reaction mixture
consisting of 45 mM Tris-HCl (pH 8.0), 67 µM (NH4)2Fe(SO4)2·6H2O, 0.9 mM 2-
ketoglutarate, 1.8 mM L-ascorbic acid, 10 ng/µL tRNA, 1.25 µM E. coli wild-type
AlkB, and 0.125 µM E. coli AlkB L118V/D135S mutant. The demethylated RNA
was extracted by phenol–chloroform–isoamylalcohol (PCI) and chloroform, fol-
lowed with ethanol precipitation.
The demethylated RNA (5 µg) was dissolved in 15 μL of CMC-BEU buffer
[0.34 M CMC, 7M urea, 4 mM EDTA, 50 mM bicine (pH 7.88)] and incubated at
37 °C for 20 min. For the CMC-minus control sample, the same reaction was
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performed without CMC. The reaction was quenched by addition of 100 μL stop
solution [0.3 M NaOAc (pH 5.2), 0.1 M EDTA]. After ethanol precipitation, the
tRNA pellet was dissolved in 40 μL of 50 mM sodium carbonate buffer (pH 10.4)
and incubated at 37 °C for 4 h to remove CMC from U or G bases. The CMC-
treated and untreated tRNAs were 3′ dephosphoryled at 37 °C for 1 h in a mixture
containing 100 mM Tris-HCl (pH 6.8), 10 mM MgCl2, 2 mM DTT, and 0.2 U/µL
T4 polynucleotide kinase (NEB), and then subjected to PCI and chloroform
extractions and ethanol precipitation. The prepared RNA (200 ng) was ligated with
3′ RNA linker at 25 °C for 16 h in a mixture containing 1 × T4 RNA Ligase
Reaction Buffer (NEB), 1 µM Universal miRNA cloning linker (NEB), 15%
PEG8000, 2 U/µL SUPERase•In (Invitrogen), and 10 U/µL T4 RNA ligase 2,
truncated KQ (NEB), followed by PCI and chloroform extractions and ethanol
precipitation. The ligated product was resolved and separated from the excess 3′
adaptor by running 10% PAGE with 7 M urea, excised from the gel, eluted from the
gel pieces, and ethanol precipitated.
Next, half of the adaptor-ligated tRNA was dissolved in 11.2 µL water and
0.8 µL RT primer (3.75 µM) (Supplementary Data 6) was added, denatured at 80 °C
for 5 min, and placed at room temperature for several minutes. Then, 8 μL TGIRT
Reaction Buffer [Tris-HCl pH 7.5 (20 mM, final), 5 mM MgCl2 (20 mM, final),
NaCl (450 mM, final), dNTPs (1 mM, final), DTT (5 mM, final), SUPERase•In
(1 U/µL, final), and TGIRT-III (InGex, 5%, final)] were added to the denatured
tRNA-primer mix, and reverse transcription was performed at 57 °C for 2 h. The
reaction was quenched, and the template tRNA was degraded by addition of 1.1 µL
of 2M NaOH and incubation at 95 °C for 5 min, followed by ethanol precipitation.
The first-strand cDNA was resolved by running 6% PAGE with 7 M urea, excised
from the gel, eluted from the gel pieces, and ethanol precipitated.
Half of the cDNA was circularized at 60 °C for 18 h in a mixture containing 1×
CircLigase Reaction buffer, 2.5 mM MnCl2, 50 µM ATP, and 5 U/µL CircLigase II
(Lucigen), followed by heat inactivation at 80 °C for 10 min. The circularized
cDNA was extracted by PCI and chloroform extractions, and ethanol precipitated.
One-fourth of the circularized cDNA was PCR-amplified with 15 cycles in a
mixture containing 1 × Phusion GC Buffer, 0.2 mM dNTPs, 0.5 µM forward and
reverse PCR primer (Supplementary Data 6), 3% DMSO, and 20 U/mL phusion
polymerase (NEB). The PCR product was then collected with AMPure XP
(Beckman Coulter), resolved by 6% native PAGE, excised from the gel, eluted from
the gel pieces, and purified by AMPure XP. The cDNA libraries were sequenced in
100-bp paired-end mode on an Illumina HiSeq4000 platform.
Data analysis of tRNA-Ψ-seq. Raw reads from Illumina sequencing were sub-
jected to adaptor trimming and filtering of low-quality reads by fastp 0.20.0
(https://github.com/OpenGene/fastp). The minimum length for reads after trim-
ming was set to 15 nucleotides, and the quality threshold was set to Q15. The
trimmed reads were mapped to the human mitochondrial tRNA sequence
(obtained from NCBI and manually curated) with 10 Ns on both sides using
Bowtie2 version.2.3.3.1(http://bowtie-bio.sourceforge.net/bowtie2/index.shtml).
Properly paired reads that overlapped with the CCA terminal sequence of tRNA for
at least one nucleotide and did not overlap with the 3′ trailer sequence were used
for the Ψ score calculation. A summary of trimming and mapping is provided in
Supplementary Data 7. Based on the 5′ end position and mutations in the mapped
reads, the Ψ score at the reference position x was obtained by the following Eq. (1).
Ψ score ¼ rm xð Þ
rm x þ 1ð Þ 
rp xð Þ
rp x þ 1ð Þ
 
 rm x þ 1ð Þ
rm x þ 2ð Þ 
rp x þ 1ð Þ




Function rm(x) returns the number of reads piled up at position x in the CMC-
minus sample, and function rp(x) returns the number in the CMC-plus sample.
When the leftmost or penultimate nucleotide is a mismatch against the reference,
the 5′ end of the read is shifted to the 3′ side of the mismatch. The final Ψ score is
the average of the two replicates. The calculations were carried out by a Python
script (http://python.org), utilizing the libraries Pysam (https://github.com/pysam-
developers/pysam) and Biopython104. All the custom scripts used in this analysis
are available upon request.
Post-labeling method to determine the tRNA modifications. The post-labeling
method was basically performed as instructed in a procedure105. In brief, purified
tRNAGlu was partially hydrolyzed by heat treatment. The 5′ terminus of each
fragment in the hydrolysate was 32P-phosphorylated with T4 polynucleotide kinase
(Toyobo). The radiolabeled fragments were resolved on 12% PAGE with 7M urea
and visualized on a fluoroimager (FLA-7000, Fujifilm), and each band was excised
from the gel. The fragment was eluted from the gel piece and digested with
nuclease P1. The 32P-labeled 5′-terminal nucleotide of each fragment was analyzed
by 2D-TLC with cellulose plates using the solvent system consisting of isobutyric
acid/concentrated ammonia/H2O (66:1:33 v/v/v) in the first dimension and 2-
propanol/HCl/H2O (70:15:15 v/v/v) in the second dimension. The radiolabeled
spots on the TLC plates were visualized on a fluoroimager (FLA-7000, Fujifilm).
The corresponding modified nucleotide was determined by referring to a 2D-TLC
map of modified nucleotides106.
Construction of QTRT1 or QTRT2 KO cell lines. QTRT1 or QTRT2 KO
HEK293T cells were generated using the CRISPR/Cas9 system94,107. In short, sense
and antisense oligonucleotides corresponding to the single guide RNA (sgRNA)
(Supplementary Data 6) were cloned into pX330 vector (Addgene #42230)108.
HEK293T cells seeded in 24-well plates were transfected using FuGENE HD
(Promega) with 300 ng pX330 containing the designed sgRNA sequence, 100 ng of
pEGFP-N1 (Clontech) to monitor transfection efficiency by EGFP fluorescence,
and 100 ng of a modified pLL3.7 containing a puromycin-resistance gene. One day
after transfection, cells were seeded at low density, and transfectants were selected
with 1 μg/mL puromycin. Eight days after transfection, several colonies were picked
and further grown for several days. The genomic region targeted by the sgRNA in
each clone was PCR-amplified and sequenced; primers are listed in Supplementary
Data 6. WT and the KO HEK293T cell lines were cultured at 37 °C in 5% CO2 in
DMEM (D5796, Sigma-Aldrich) supplemented with 5% fetal bovine serum
(Gibco), 1% penicillin–streptomycin (Fujifilm Wako Pure Chemical Corporation),
and 140 nM queuine.
Mitoribosome profiling
Library preparation. The cell extracts were prepared with lysis buffer94,109 sup-
plemented with 100 μg/mL chloramphenicol, treated with 15 U of TURBO DNase
(Thermo Fisher Scientific), and clarified by centrifugation at 20,000 × g, 4 °C for 10
min. The RNA content in the lysate was measured with the Qubit RNA BR Assay
Kit (Thermo Fisher Scientific). The lysate containing 10 μg of RNA was digested
with 20 U of RNase I (Lucigen). The ribosomes were pelleted by sucrose cushion
with ultracentrifugation. After RNA extraction with TRIzol (Thermo Fisher Sci-
entific) and Direct-zol RNA microprep kit (Zymo research), the protected RNA
fragments ranging from 17 to 34 nt were gel-excised. Following, depho-
sphorylation, linker ligation, reverse transcription, and circularization94,109, the
libraries were PCR-amplified and sequenced on an Illumina HiSeq4000 platform
(single-end 50 bp read). See Supplemental Data 6 for the details for DNA/RNA
oligonucleotides used in the library preparation.
Data analysis. After trimming the linker sequences, all reads were first aligned to
human non-coding RNAs (rRNAs, tRNAs, mt-rRNAs, mt-tRNAs, snRNAs,
snoRNAs, and miRNAs) by STAR110. Then, the un-aligned reads were mapped to
the custom-made mitochondrial transcript sequences2,111 by STAR. On the
mitochondrial footprints, the distances from 5′ end to the ribosomal A site were
estimated as follows: 14 for 23- to 31-nt long reads and 15 for 32 to 34-nt long
reads. Then, the reads on given A-site codon were assigned, using Riboseq tools
(https://github.com/ingolia-lab/RiboSeq).
For calculation of codon occupancies, the reads at each codon were normalized
with averaged reads per codon in the transcript. Codon positions with codon
occupancy lower than 5% in each transcript in any two or more samples among WT
replication 1, WT replication 2, QTRT2 KO replication 1, and QTRT2 KO replication
2 were removed from analysis. Start and stop codons were also omitted from the
analysis. All the custom scripts used in this study are available upon request.
Protein aggregation assay. The reporter plasmids encoding firefly luciferase fused
with enhanced green fluorescent protein (Fluc-EGFP) and its structurally desta-
bilized mutants, FlucSM-EGFP (R188Q mutant) and FlucDM-EGFP (R188Q/
R261Q mutant), were obtained from Addgene (#90170–#90172, respectively)72.
Wild type and QTRT2 KO HEK293T cells (3.5 × 105 cells/well) were cultured in
six-well plates (IWAKI) for 24 h, followed by transfection with 3 μg of each
reporter plasmid using FuGENE HD (Promega). After 48 h, ten fluorescence
images per well were acquired using a fluorescence microscope (AF6500 System,
Leica Microsystems) equipped with an objective lens (HCX PL FLUOTAR 10×/
0.30 DRY; Leica Microsystems) in the setting as follows: Chanel, GFP; Exposure
time, 100 ms; Gain, 1; Intensity, 5. To count the number of foci which represent
reporter protein aggregates, the images were processed by ImageJ software. The
macrocode was set as follows: run(“Subtract Background…”, “rolling=15”); run
(“8-bit”); setAutoThreshold(“Default dark”); setThreshold(33, 255); setOption
(“BlackBackground”, true); run(“Convert to Mask”); run(“Analyze Particles…”,
“include summarize”). To estimate transfection efficiency, the area of EGFP
fluorescence was obtained by the same macro code as above, except setThreshold
(33, 255) was replaced by setThreshold(4, 255). Aggregation rate was calculated as
the number of aggregates divided by the area of EGFP fluorescence. Statistical
analyses were performed with R.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 3c, 6d and Supplementary Fig. 4 are provided as a
Source Data file. Data for tRNA-Ψ-seq and ribosome profiling generated in this study
have been deposited in NCBI SRA (PRJNA638467) and GEO (GSE150439), respectively.
The tRNA sequences including modifications have been deposited in DDBJ with the
accession codes LC530712, LC530713, LC530714, LC530715, LC530716, LC530717,
LC530718, LC530719, LC530720, LC530721, LC530722, LC530723, LC530724,
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LC530725, and LC530726 for mt-tRNAs for Ala, Cys, Glu, Phe, Gly, His, Met, Asn, Pro,
Gln, Arg, Thr, Val, Trp, and Tyr, respectively. tRNA sequences are also accessible at our
web site: http://rna.chem.t.u-tokyo.ac.jp/trnadata/hsmttrna/mttrnas.html. All data
supporting the findings in this study are available from the corresponding author upon
reasonable request. Source data are provided with this paper.
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